Main menu


You are here

Complexity

AstraZeneca: Blot Clots apparently Stem From Rare Antibody Reaction

New research has identified unusual antibodies that appear to have caused, in rare cases, serious and sometimes fatal blood clots in people who received the Covid vaccine made by AstraZeneca.

Exactly why the rare reactions to the vaccine occurred is still a mystery.

Scientific teams from Germany and Norway found that people who developed the clots after vaccination had produced antibodies that activated their platelets, a blood component involved in clotting. The new reports add extensive details to what the researchers have already stated publicly about the blood disorder.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

COVID "Long haulers" --more background on their problems

How many people get ‘long COVID’ – and who is most at risk?

A few months ago, a young athletic guy came into my clinic where I’m an infectious disease physician and COVID-19 immunology researcher. He felt tired all the time, and, importantly to him, was having difficulty mountain biking. Three months earlier, he had tested positive for COVID-19. He is the kind of person you might expect to have a few days of mild symptoms before recovering fully. But when he walked into my clinic, he was still experiencing symptoms of COVID-19 and he could not mountain bike at the level he was able to before.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

The difficulties in enrolling teenagers for vaccine test trials.

 

 

Teenagers contract the novel coronavirus almost twice as often as younger children but vaccines authorized in the United States are mostly for adults — Moderna’s for 18 and older, Pfizer’s for 16 and up.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Vaccine distribution problems: complicated by use of algorithms

Faced with the daunting task of parceling out a limited supply of coronavirus vaccines, Trump administration officials came up with a seemingly simple formula last year to streamline distribution of the shots.

First, federal administrators would run an automated algorithm to divide vaccine doses nationwide, based on the size of each state’s adult population. Then each state would decide how to dole out the shots to local hospitals, nursing homes and clinics.

But rather than streamline vaccine distribution, public health experts say, the algorithm has increased the burden for many states. It requires them to come up with multiple delivery plans for their weekly quotas of Pfizer and Moderna shots, even if the different shipments are destined for the same clinics and hospitals.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Complexity
howdy folks